Enspryng Euroopan unioni - suomi - EMA (European Medicines Agency)

enspryng

roche registration gmbh - satralizumab - neuromyelitis optica - immunosuppressantit - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Ronapreve Euroopan unioni - suomi - EMA (European Medicines Agency)

ronapreve

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - immunoseerumit ja immunoglobuliinit, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. katso kohdat 4. 4 ja 5.

Gavreto Euroopan unioni - suomi - EMA (European Medicines Agency)

gavreto

roche registration gmbh  - pralsetinib - karsinooma, ei-pienisoluinen keuhko - antineoplastiset aineet - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.

Lunsumio Euroopan unioni - suomi - EMA (European Medicines Agency)

lunsumio

roche registration gmbh - mosunetuzumab - lymfooma, follicular - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Vabysmo Euroopan unioni - suomi - EMA (European Medicines Agency)

vabysmo

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - silmätautien - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Columvi Euroopan unioni - suomi - EMA (European Medicines Agency)

columvi

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - antineoplastiset aineet - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.

LIPOCOMB 10 mg / 10 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

lipocomb 10 mg / 10 mg kapseli, kova

egis pharmaceuticals public limited company - rosuvastatinum sinkki,ezetimibum - kapseli, kova - 10 mg / 10 mg - rosuvastatiini ja etsetimibi

LIPOCOMB 20 mg / 10 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

lipocomb 20 mg / 10 mg kapseli, kova

egis pharmaceuticals public limited company - rosuvastatinum sinkki,ezetimibum - kapseli, kova - 20 mg / 10 mg - rosuvastatiini ja etsetimibi

LIPOCOMB 40 mg / 10 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

lipocomb 40 mg / 10 mg kapseli, kova

egis pharmaceuticals public limited company - rosuvastatinum sinkki,ezetimibum - kapseli, kova - 40 mg / 10 mg - rosuvastatiini ja etsetimibi

Blomensy 20 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

blomensy 20 mg tabletti, kalvopäällysteinen

egis pharmaceuticals plc - rivaroxaban - tabletti, kalvopäällysteinen - 20 mg - rivaroksabaani